Literature DB >> 22376172

Glycosylated hemoglobin and outcomes in diabetic patients with acute myocardial infarction after successful revascularization with stent placement: findings from the guthrie health off-label stent (GHOST) investigators.

Anand Singla1, Pamela Orshaw, Judy Boura, Kishore J Harjai.   

Abstract

OBJECTIVE: We evaluated the influence of glycemic control on cardiovascular outcomes in diabetic patients with acute myocardial infarction (AMI) who underwent successful percutaneous coronary intervention (PCI) with stent placement.
BACKGROUND: In patients presenting with AMI, diabetic status confers adverse cardiovascular outcomes after PCI. However, the influence of glycemic control on outcomes after successful PCI is less well studied.
METHODS: We examined 231 consecutive diabetes mellitus (DM) patients with AMI who underwent successful primary PCI and had evaluation of glycosylated hemoglobin (HbA1c) from 30 days before to 90 days after AMI. Patients were categorized in 2 groups, controlled DM with HbA1c ≤ 7.0 (N = 83, 36%) and uncontrolled DM with HbA1c > 7.0 (N = 148, 64%). We assessed 12-month cardiovascular outcomes in study groups.
RESULTS: Uncontrolled diabetics were younger, tended to be less hypertensive, and had higher baseline glomerular filtration rate and final vessel diameter compared to controlled diabetics. Uncontrolled DM patients had similar major adverse cardiovascular events (MACE; composite of all-cause death, MI, target vessel revascularization [TVR], and stent thrombosis [ST]; 20% vs. 30%, log-rank P = 0.54), death (8.8% vs. 12%, P = 0.40), MI (8.8% vs. 9.6%, P = 0.76), TVR (9.5% vs. 8.4%, P = 0.95), and ST (3.4% vs. 4.8%, P = 0.54) as the controlled diabetics. In Cox regression analysis, after adjustment for baseline differences, glycemic control had no independent influence on study outcomes.
CONCLUSION: Glycemic control, determined by HbA1c, does not seem to influence cardiovascular outcomes in diabetic patients with AMI after successful stent placement. ©2012, Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22376172     DOI: 10.1111/j.1540-8183.2011.00715.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  5 in total

1.  Glycemic Control in Coronary Revascularization.

Authors:  Francisco Ujueta; Ephraim N Weiss; Steven P Sedlis; Binita Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

2.  The relationship between glycated hemoglobin and complexity of coronary artery lesions among older patients with diabetes mellitus.

Authors:  Jinling Ma; Xiujie Wang; Yutang Wang; Yuexiang Zhao; Meng Gao; Xiaoqian Li
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

Review 3.  Association Between Glycosylated Hemoglobin Level and Cardiovascular Outcomes in Diabetic Patients After Percutaneous Coronary Intervention.

Authors:  Jia Zheng; Jing Cheng; Qian Zhang; Cuijuan Qi; Tong Wang; Xinhua Xiao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

4.  Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Hamdi Pusuroglu; Ozgur Akgul; Huseyin Altug Cakmak; Mehmet Erturk; Ozgur Surgit; Omer Celik; Derya Ozturk; Fatih Uzun; Emre Akkaya; Aydın Yildirim
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-09-11       Impact factor: 1.426

5.  An Elevated Glycemic Gap is Associated with Adverse Outcomes in Diabetic Patients with Acute Myocardial Infarction.

Authors:  Wen-I Liao; Chin-Sheng Lin; Chien-Hsing Lee; Ya-Chieh Wu; Wei-Chou Chang; Chin-Wang Hsu; Jen-Chun Wang; Shih-Hung Tsai
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.